rare

Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder

Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi companyKER-0193, a novel, orally bioavailable…

3 months ago

Limited Drop, Maximum Flex: Cleveland Golf and SWAG Partner for RTZ Wedge Collaboration

HUNTINGTON BEACH, Calif., Aug. 28, 2025 – When pure contact meets unfiltered creativity, something special happens. Introducing the Cleveland Golf…

3 months ago

London musician with brain tumour inspires Brighton triathlon fundraiser

Tuesday 26 August, 2025 A talented musician from London, who died from a rare brain tumour in January this year…

3 months ago

A Life Rewritten: KFSHRC Treats Rare Disease After 22 Years of Specialized Care

RIYADH, Saudi Arabia, Aug. 24, 2025 (GLOBE NEWSWIRE) -- In a rare example of a lifelong bond between a patient…

3 months ago

UltraLuxe Singapore 2025 Showcases The Collectable And Investible In Niche Luxury Through Immersive And Social Experiences

SINGAPORE, Aug. 20, 2025 /PRNewswire/ -- From jewellery and fashion to art, wellness, gastronomy, and lifestyle, UltraLuxe returns for its fourth…

3 months ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company…

3 months ago

FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…

4 months ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical…

4 months ago

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

CHICAGO, July 16, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with…

4 months ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025 16:16 ET  | Source: Rhythm Pharmaceuticals, Inc. BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.…

5 months ago